Inmode Corporate Presentation

1. INMODE PROFILE MAY 2022

2. OVERVIEW

3. INMODE: WHO WE ARE
Leading global provider of innovative, minimally-invasive aesthetic and wellness solutions, with strong brand recognition
Broad radiofrequency (“RF”) based portfolio (capital and consumables) providing specialized aesthetic and wellness solutions to plastic
surgeons, dermatologists, OB/GYNs, ENTs and ophthalmologists
Worldwide regulatory approvals supported by extensive peer-reviewed published clinical data
Demonstrated history of profitable growth
Global platform with an established direct sales force and extensive distributor network
Pipeline to expand medical offerings and adapt proprietary RF technologies to specific applications for plastic and aesthetic surgeons,
OB/GYNs, ENTs and ophthalmologists
Proven management team with extensive business, scientific and technology experience and expertise
1
2
3
4
5
6
7

4. $85.9M
Q1-2022 Revenue
$113.0-$113.3M
Q2-2022 Revenue Guidance
$425-$435M
Full Year 2022 Revenue
Guidance
$0.40
Q1-2022 Non-GAAP Diluted
Earning per Share Pre-Split
6,100
US Installed Base
12,700
Unit Installed Worldwide
8 Patented
Technologies Across
10Product Families
189
Direct Sales Reps
Selling in
77
Countries
$34.1M
Q1-2022
Non-GAAP
Net Income
INMODE Q1/Q2 2022: BY THE NUMBERS

5. INMODE GLOBAL ORGANISATION SELLING IN 77 COUNTRIES
397 employees worldwide, including 189 direct sales reps and 35 person R&D team
• 157 person direct sales force in the US
and Canada
• Logistics Centers in L.A. and Toronto
• Distributors by country in South America
• Sales and marketing office in Buenos
Aires, Argentina
• Wholly-owned subsidiaries in Spain,
France, UK and Italy
• Distributors by country
• Middle East countries via UK
• Corporate headquarters
• R&D and engineering center
• Manufacturing and logistics
• Corporate finance
• Wholly-owned subsidiaries in Israel
• Exclusive distributors by country
• Sales and marketing office in Hong
Kong
• Wholly-owned subsidiaries in Australia,
India and China
AMERICAS EUROPE ISRAEL ASIA

6. THE EVOLVING
AESTHETICS MARKET

7. A
✓ 40 million procedures annually
worldwide
✓ Non-invasive, in-office, topical
procedures
✓ Typical treatments: hair removal,
pigmented lesions, vascular lesions,
leg veins, acne
✓ Multiple treatments and limited
efficacy
✓ Demographics: 35-60 yrs. old
✓ Looking for comparable results to
plastic surgery, but without the
shortcomings of full surgery including:
▪ Anaesthesia, downtime, scars
✓ Large population of patients whose
skin is not responsive to other skin
tightening modalities
✓ Affordable, office-based, out-patient
procedure
✓ 2.5 million procedures annually
worldwide
✓ Full surgical procedure, with
general anaesthesia
✓ Lengthy downtime
✓ High cost
✓ Incisions and scars
✓ Low repeatability, dependent on
the doctor’s technique
PLASTIC SURGERY
THE “TREATMENT GAP”
LASER PROCEDURES
Significant opportunity for innovative and differentiated minimally-invasive solutions
Significant opportunity for InMode to invent and develop minimally-invasive
technologies and products for the “Treatment Gap” category
________________________
Source: Medical Insights (2017), ASAPS (2018).

8. SOLUTION FOR THE TREATMENT GAP – EVOLUTIONARY PROGRESS
Traditional laser companies
INMODE

9. AESTHETICS INDUSTRY UNDERGOING A PARADIGM SHIFT
To: Minimally-Invasive/Ablative Aesthetic Surgery
From: Traditional Laser-Based Aesthetics
• In-office procedures – mainly hair removal
• Non-invasive laser-based procedures
• Very limited results that typically require multiple
treatments
• Patients are seeking new procedures with more
significant and longer-lasting results
• Growing demand for face and body contouring
and not just “laser” rejuvenation or hair removal
The new competitive dynamics of the aesthetic surgery industry require a major technological change and a new product portfolio
“Treatment Gap” patients are increasingly looking for solutions that address the
shortcomings of laser-based aesthetics and the complexity of full surgery

10. WHO DO WE SERVE?
InMode’s Major Customers
In response to physicians’ desires to expand their offering of our aesthetic and wellness office-based
procedures, we are developing additional RF solutions targeting their specialties
________________________
Source: Medical Insights (2017), ASAPS (2018)
Source: Doctors’ Associations. Note: Estimates based on 2018 data.
• 100,000+ surgically-trained physicians in the U.S.
and 200,000+ globally
• While not all of these physicians focus on
aesthetics, many do perform aesthetic
procedures
• Interested in adding specific medical / wellness
procedures related to their area of expertise
• “Private pay procedures augment physicians”
income – office-based procedures

11. INMODE SOLUTION:
PROPRIETARY TECHNOLOGY

12. DEEP SUBDERMAL FRACTIONAL RF
InMode Proprietary Technology
Deep Subdermal Fractional RF
High-quality results with fewer treatments and shorter downtimes than full aesthetic solutions
✓ Delivers RF energy under the dermis through an array of needle electrodes producing localised heat and small pinpoint coagulation
✓ Can be used for wrinkle treatment, skin tightening, cellulite and acne scars
✓ Heat generated by pins in the sub-dermal tissue promotes both collagen remodelling and fat melting

13. MORPHEUS8 BODY - BURST MODALITY ANIMATION

14. BEFORE
FACE & NECK USING DEEP SUBDERMAL FRACTIONAL RF
AFTER
“After” results reflect 3 treatments 6 weeks apart
___________________________
Note: These are sample results and may not be indicative of actual results.

15. BEFORE
BODY USING DEEP SUBDERMAL FRACTIONAL RF
AFTER
“After” results reflect 2 treatments 4 weeks apart
___________________________
Note: These are sample results and may not be indicative of actual results.

16. INMODE’S EXISTING PORTFOLIO OF TECHNOLOGIES
Since 2010, InMode has launched multiple innovative product platforms
Surgical/RFAL, SARD Hands-Free ‘Traditional’/ Laser
Optimas Contoura
EmpowerRF Triton
Face Women’s
Wellness
Body Hair
Removal
BodyFX
MiniFX
Plus
Triton Duo Light
Triton Duo Dark
FormaV
EmbraceRF
Face
FaceTite
Morpheus8
AccuTite Forma
Lumecca DiolazeXL
Vasculaze
Body
Platform
Application
Handpieces
FaceTite /
NeckTite
BodyTite EvolveX
Evoke
Face Body
Cheek
Chin
BodyTite Tite
Tone
Morpheus8
Face &
Body
Morpheus8V
Morpheus8 vTone
Morpheus8
Body
Morpheus8
Morpheus8
Body
AccuTite Transform

17. DEMONSTRATED HISTORY OF PROFITABLE GROWTH
Revenue / Non-GAAP Net Income
($ in millions)
Revenue Non-GAAP Net Income
• High profitability; 84%-86% gross margins
• InMode technologies have sustainable cost advantage
• Outsourced manufacturing at fixed cost per unit
• Long-term agreements with Medimor and Flex for major
parts and sub-systems
• Controls procurement of major components and quality
assurance
• Sustainable tax advantage
• Facilities are in highest tax benefit zone within Israel
• Starting from 2022, the Company’s corporate tax rate is
expected to be between 7.5% to 10%.
23.1
53.5
100.2
156.4
206.1
357.6
65.5
87.3 94.2
110.5
85.9
2.4 10.8
31.9
62.2
89.1
176.3
29.4
43.9 48.1 55.2
34.1
0.0
100.0
200.0
300.0
400.0
2016 2017 2018 2019 2020 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022

18. INMODE QUALITY MEDICAL MANUFACTURING

19. MARKETING TO MEDICAL FOCUS - KEY OPINION LEADERS & LUMINARIES
Podium Presentations | Clinical Trials | Publications |Training | Reference Calls | Media
Dr. Sherrell Aston Dr. Christine Hamori
Dr. Christopher Chia
Dr. Erez Dayan
Dr. Rod Rohrich

20. LEADER IN CLINICAL EXCELLENCE
65+ Peer Reviewed Publications to Date
“The mean skin surface area reduction was
25.8% in regions treated with radiofrequency
plus SAL at 6 weeks, and increased to 36.4% at 1
year.”
- Aesthetic Surgery Journal
“RFAL with its safety features presents an
alternative to SupL, which has a higher
complication rate, risk for contour
deformities, and steeper learning curve.”
- PRS Global Open
“The novel RFAL technology offers
immediate skin tightening effect that
is stable over time.”
- JCDSA
“This technology allows precise soft tissue
modeling at multiple levels to enhance
results over traditional suction-assisted
lipecectomy.”
- Aesthetic Plastic Surgery

21. BUSINESS | CONSUMER | INDUSTRY RECOGNITION